APG101_CD_002: A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma.
Martin Bendszus
No relevant relationships to disclose
Jürgen Debus
No relevant relationships to disclose
Wolfgang Wick
Consultant or Advisory Role - Antisense Pharma; Magforce; Merck Serono (U); Merck Sharp & Dohme; Roche/Genentech
Honoraria - Medac; Merck Serono; Roche/Genentech
Research Funding - Apogenix; Lilly; Merck Sharp & Dohme
Grigory Kobyakov
No relevant relationships to disclose
Tobias Martens
No relevant relationships to disclose
Oliver Heese
No relevant relationships to disclose
Josef Pichler
No relevant relationships to disclose
Roger Stupp
No relevant relationships to disclose
Claudia Kunz
Employment or Leadership Position - Apogenix
Harald Fricke
Employment or Leadership Position - Apogenix